COLUMBUS, Ohio, Jan. 12, 2016 /PRNewswire/ -- Details regarding a breakthrough medical discovery with tremendous potential for treatment of patients with serious bacterial infections were presented on January 11 to pharmaceutical leaders and public and private investors attending the 8th Annual Biotech Showcase in San Francisco.
Logo - http://photos.prnewswire.com/prnh/20160111/321018LOGO
Steven Goodman, Ph.D., a member of the Scientific Board for ProclaRx and Associate Professor of Pediatrics at the Ohio State College of Medicine, and Principal Investigator at the Research Institute of Nationwide Children's Hospital, spoke about a new technology developed by ProclaRx, an Ohio-based biotechnology company, to break down and destroy biofilms. Biofilms are a physical barrier which protect bacteria and prevent antibiotics and the body's immune system from eradicating chronic infections.
Infections with biofilms are associated with indications as those found in advanced wound care, chronic draining ear infections, and CVID sinusitis. They are highly resistant to antibiotics and have a significant ability to evade normal defenses against bacteria. Recurrent infections and antibiotic resistance is a major clinical and public health problem, with bacterial biofilms implicated in more than 80% of infections.
"The anti-biofilm technology will fundamentally change the way persistent bacterial infections are treated. This recent discovery offers the opportunity to invest in real world products to help combat chronic bacterial diseases," stated Nick Henderson, Chairman of the Board for ProclaRx.
Founded in 2014, ProclaRx has exclusive worldwide rights to develop and commercialize anti-infective technology from Nationwide Children's Hospital and the University of Southern California. With $5.5 million invested to-date, they are seeking additional financing and strategic partners. The Biotech Showcase is one of the healthcare industry's largest annual healthcare investor conferences.
About ProclaRx
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, secretory otitis media and CVID sinusitis. Visit www.proclarx.com or call 949-302-2165 or e-mail info@proclarx.com.
Contact: Dr. Joseph D. Kittle, Jr.
CEO, ProclaRx
949-302-2165
SOURCE ProclaRx
